Ejection fraction (EF) measures the amount of blood pumped out of your heart's lower chambers, or ventricles. It's the percentage of blood that leaves your ventricle when your heart contracts. The ...

Heart failure is a heterogeneous syndrome. Approximately 30–50% of patients with heart failure have normal or near normal left ventricle function. Several epidemiological studies confirm that the ...

Sacubitril/valsartan (Entresto) became the first drug to get a broad heart failure indication that reaches into the normal ejection fraction range for prevention of cardiovascular death and ...

Jim Januzzi, MD, outlines a multitude of drug treatment options for heart failure revolving around patient ejection fraction (EF) status. Ryan Haumschild, PharmD, MS, MBA: As we start to transition ...

In a meta-analysis involving 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up.

Among patients with heart failure with preserved ejection fraction (HFpEF), lower versus higher ranges of EF signal fundamentally different morphologies and hemodynamic responses, which may have ...

The sensor prevented hospitalizations regardless of patients' ejection fraction, preserved ejection fraction (50 percent or higher, which is considered normal), reduced ejection fraction (<40 percent) ...

Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart ...

The DELIVER trial is the largest trial to date of SGLT2 inhibitor use in heart failure, and these latest data on dapagliflozin in heart failure with mildly reduced or preserved ejection fraction show ...

BARCELONA, Spain—(UPDATED) Full results of the DELIVER trial, flanked by several other analyses, demonstrate that the sodium-glucose cotransporter 2 (SGLT2) inhibitors provide benefits to patients ...

In contrast to the advances in therapy for systolic HF over the past three decades, which have improved mortality rates, no therapies have been proven to reduce mortality in patients with HFNEF (Table ...